Integrin αvβ3-dependent pathogenic effect and therapeutic effects of DL-N2 combined with EGFR inhibitors in pancreatic adenocarcinoma
AbstractBackground Pancreatic adenocarcinoma (PDAC) remains one of the most lethal malignancies, characterized by aggressive progression, pronounced stromal desmoplasia, and a limited response to targeted therapies. Although epidermal growth factor receptor (EGFR) inhibitors have shown promise in preclinical studies, their clinical...
Estimand Framework Development for eGFR Slope Estimation and Comparative Analyses Across Various Estimation Methods
Abstract Chronic kidney disease (CKD) is a global health challenge characterized by progressive kidney function decline, often culminating in end-stage kidney disease (ESKD) and increased mortality. To address the limitations such as the extended trial follow-up necessitated by the low...
Promatix Biosciences Presents Positive Preclinical Data with First-in-Class PBS293 EGFR×EphA2 Cis-Bispecific ADC Demonstrating Enhanced Tumour Selectivity
Data presented at 16th World ADC London Summit with lead programme in colorectal cancer highlight the promise of Promatix’s proteomics-based platform to optimise cis-bispecific antibody-drug conjugate (ADC) discovery and designDual-antigen targeting strategy utilises hybrid avidity-gated binding to improve tumour cell...
Promatix Biosciences Presents Positive Preclinical Data with First-in-Class PBS293 EGFR×EphA2 Cis-Bispecific ADC Demonstrating Enhanced Tumour Selectivity
Für Sie zusammengefasst PBS293 50x potency vs cetuximab lower skin tox Dual EGFR x EphA2 targets via proteomics TxPro Poster at ADC: hybrid avidity ADC spares skin. EQS-News: Promatix Biosciences, Ltd. / Key word(s): Study/Study results Promatix Biosciences Presents Positive...
B7-H3-mediated cis-inhibition of EGFR by a tumor-selective bispecific antibody enhances anti-tumor efficacy and minimizes toxicities
Therapeutic targeting of epidermal growth factor receptor (EGFR) in solid tumors faces significant limitations due to on-target/off-tumor toxicities, underscoring the urgent need for tumor-selective anti-EGFR therapies. Comprehensive bioinformatics and histopathological analyses identify marked upregulation of B7-H3 across EGFR-positive malignancies, contrasting...
Johnson & Johnson : Subcutaneous RYBREVANT®▼ (amivantamab) approved by European Commission for every-three-week and every-four-week dosing for patients with advanced EGFR-mutated non-small cell lung cancer
Johnson & Johnson : Subcutaneous RYBREVANT®▼ (amivantamab) approved by European Commission for every-three-week and every-four-week dosing for patients with advanced EGFR-mutated non-small cell lung cancer Published on 02/23/2026 at 11:20 am EST Publicnow Share JOHNSON & JOHNSON +1.21%Home/ Media Center/...